Concordant bone marrow involvement of diffuse large B-cell lymphoma represents a distinct clinical and biological entity in the era of immunotherapy

A new extranodal scoring system based on the prognostically relevant extranodal sites in diffuse large B-cell lymphoma, not otherwise specified treated with chemoimmunotherapy

(2016) Hee Sang Hwang et al.   ANNALS OF HEMATOLOGY

The 2016 revision of the World Health Organization classification of lymphoid neoplasms

(2016) S. H. Swerdlow et al.   BLOOD

Randomized phase 3 study in low-grade lymphoma comparing maintenance anti-CD20 antibody with observation after induction therapy: A trial of the ECOG-ACRIN Cancer Research Group (E1496)

(2016) Stefan K. Barta et al.   CANCER

Central nervous system prophylaxis in diffuse large B-cell lymphoma

(2016) Mohammad Faizan Zahid et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Rituximab maintenance versus observation alone in patients with chronic lymphocytic leukaemia who respond to first-line or second-line rituximab-containing chemoimmunotherapy: final results of the AGMT CLL-8a Mabtenance randomised trial

(2016) Richard Greil et al.   Lancet Haematology

Cell of origin of transformed follicular lymphoma

(2015) R. Kridel et al.   BLOOD

Front-line, dose-escalated immunochemotherapy is associated with a significant progression-free survival advantage in patients with double-hit lymphomas: a systematic review and meta-analysis

(2015) Christina Howlett et al.   BRITISH JOURNAL OF HAEMATOLOGY

Prognostic impact of concordant and discordant bone marrow involvement and cell-of-origin in Korean patients with diffuse large B-cell lymphoma treated with R-CHOP

(2015) Mi-Jung Park et al.   JOURNAL OF CLINICAL PATHOLOGY

Primary testicular diffuse large B-cell lymphoma displays distinct clinical and biological features for treatment failure in rituximab era: a report from the International PTL Consortium

(2015) L Deng et al.   LEUKEMIA

Clinical and biological significance of de novo CD5+ diffuse large B-cell lymphoma in Western countries

(2015) Zijun Y. Xu-Monette et al.   Oncotarget

Tim-3 and Tim-4 as the potential targets for antitumor therapy

(2015) Lin Cheng et al.   Human Vaccines & Immunotherapeutics

Prognostic factors for diffuse large B-cell lymphoma in the R(X)CHOP era

(2014) R. Vaidya et al.   ANNALS OF ONCOLOGY

Long-term follow-up of dose-adjusted EPOCH plus rituximab (DA-EPOCH-R) in untreated patients with poor prognosis large B-cell lymphoma. A phase II study conducted by the Spanish PETHEMA Group

(2014) Noelia Purroy et al.   BRITISH JOURNAL OF HAEMATOLOGY

High Ki-67 expression in involved bone marrow predicts worse clinical outcome in diffuse large B cell lymphoma patients treated with R-CHOP therapy

(2014) Moo-Kon Song et al.   INTERNATIONAL JOURNAL OF HEMATOLOGY

Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification

(2014) Bruce D. Cheson et al.   JOURNAL OF CLINICAL ONCOLOGY

Immunohistochemical and Molecular Characteristics with Prognostic Significance in Diffuse Large B-Cell Lymphoma

(2014) Carmen Bellas et al.   PLoS One

MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program

(2013) S. Hu et al.   BLOOD

An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era

(2013) Z. Zhou et al.   BLOOD

Prospective phase II study of rituximab with alternating cycles of hyper-CVAD and high-dose methotrexate with cytarabine for young patients with high-risk diffuse large B-cell lymphoma

(2013) Yasuhiro Oki et al.   BRITISH JOURNAL OF HAEMATOLOGY

MYC protein expression and genetic alterations have prognostic impact in patients with diffuse large B-cell lymphoma treated with immunochemotherapy

(2013) A. Valera et al.   HAEMATOLOGICA

Prognostic impact of concordant and discordant cytomorphology of bone marrow involvement in patients with diffuse, large, B-cell lymphoma treated with R-CHOP

(2013) Hyoeun Shim et al.   JOURNAL OF CLINICAL PATHOLOGY

Rituximab, cyclophosphamide-fractionated, vincristine, doxorubicin and dexamethasone alternating with rituximab, methotrexate and cytarabine overcomes risk features associated with inferior outcomes in treatment of newly diagnosed, high-risk diffuse large B-cell lymphoma

(2013) Anthony Mato et al.   LEUKEMIA & LYMPHOMA

Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study

(2012) Z. Y. Xu-Monette et al.   BLOOD

Immunohistochemical Double-Hit Score Is a Strong Predictor of Outcome in Patients With Diffuse Large B-Cell Lymphoma Treated With Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone

(2012) Tina Marie Green et al.   JOURNAL OF CLINICAL ONCOLOGY

Comprehensive gene expression profiling and immunohistochemical studies support application of immunophenotypic algorithm for molecular subtype classification in diffuse large B-cell lymphoma: a report from the International DLBCL Rituximab-CHOP Consortium Program Study

(2012) C Visco et al.   LEUKEMIA

Cancer Invasion and the Microenvironment: Plasticity and Reciprocity

(2011) Peter Friedl et al.   CELL

BCL2 Predicts Survival in Germinal Center B-cell-like Diffuse Large B-cell Lymphoma Treated with CHOP-like Therapy and Rituximab

(2011) J. Iqbal et al.   CLINICAL CANCER RESEARCH

Impact of Concordant and Discordant Bone Marrow Involvement on Outcome in Diffuse Large B-Cell Lymphoma Treated With R-CHOP

(2011) Laurie H. Sehn et al.   JOURNAL OF CLINICAL ONCOLOGY

CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group

(2011) Michael Pfreundschuh et al.   LANCET ONCOLOGY

Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte

(2010) B. Coiffier et al.   BLOOD

Diffuse large B-cell lymphoma with concordant bone marrow involvement has peculiar genomic profile and poor clinical outcome

(2010) Ekaterina Chigrinova et al.   HEMATOLOGICAL ONCOLOGY

Standard International Prognostic Index Remains a Valid Predictor of Outcome for Patients With Aggressive CD20+B-Cell Lymphoma in the Rituximab Era

(2010) Marita Ziepert et al.   JOURNAL OF CLINICAL ONCOLOGY

Immunohistochemical Methods for Predicting Cell of Origin and Survival in Patients With Diffuse Large B-Cell Lymphoma Treated With Rituximab

(2010) Paul N. Meyer et al.   JOURNAL OF CLINICAL ONCOLOGY

A New Immunostain Algorithm Classifies Diffuse Large B-Cell Lymphoma into Molecular Subtypes with High Accuracy

(2009) W. W.L. Choi et al.   CLINICAL CANCER RESEARCH